The current clinical use of the anti-PD-1 inhibitors pembrolizumab and nivolumab and the anti-CTLA-4 therapy ipilimumab has revolutionized the survival potential of many patients with MSI-H CRC and indicates the significant anticancer potential of ICIs for CRC. The gene discussed is CTLA4; the disease is colorectal carcinoma.